Protherics PLC announces Directors Interests

| Source: Protherics PLC Protherics PLC

Cheshire, UK--(Marketwire - June 18, 2007) - 

                                 Protherics PLC

                      Notification of Directors' Interests


London, UK; Brentwood, TN, US; 18 June 2007 - Protherics PLC ("Protherics" or
the "Company"), the international biopharmaceutical company focused on critical
care and cancer, today announces that, on 15 June 2007, in accordance with
Sections 3.1.4R(1)(a) and 3.1.4R(1)(b) of the FSA Disclosure and Transparency
Rules, the Company received notification that, on 15 June 2007, Garry Watts,
Non-executive Director of Protherics, acquired 50,000 ordinary 2p shares in the
Company at a price of 58.5 pence per share.


Following the above notification, Garry Watts holds a beneficial interest in
50,000 ordinary shares in Protherics (0.01% of the issued share capital of the
Company).  The issued share capital of the Company is 339,234,721 Ordinary
Shares of 2p each.


                                   |  Ends  |



For further information please contact:


Protherics
Nick Staples, Director of Corporate Affairs                 +44 (0) 7919  480510
Julie Vickers, Company Secretary                            +44 (0)1928 518010

Financial Dynamics - press enquiries
London: Ben Atwell, Anna Keeble                             +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt                     +1 212 850 5600



Or visit  www.protherics.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange